DCGI approves India's first qHPV vaccine to treat cervical cancer

DCGI approves India's first qHPV vaccine to treat cervical cancer

Daily Current Affairs   /   DCGI approves India's first qHPV vaccine to treat cervical cancer

Change Language English Hindi

Category : National Published on: July 14 2022

Share on facebook
  • Drugs Controller General of India (DCGI) granted market authorisation to Serum Institute of India (SII) to manufacture indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.
  • Cervical cancer is the second most frequent cancer among women between 15 and 44 years of age with a high death ratio in India.
  • The approval by the drug regulator of SII’s anti-cancer vaccine followed recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on June 15.
  • Earlier the Serum Institute had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology.
Recent Post's
  • IndiGo’s parent company has brought on ex-G20 Sherpa and former NITI Aayog CEO Amitabh Kant to its board, enhancing leadership expertise.

    Read More....
  • A new Garcinia species discovered in Assam has been named Garcinia kusumae to honour Jatindra Sarma’s mother.

    Read More....
  • Mashreq Bank of UAE received in-principle approval to open a banking unit in Gujarat’s GIFT City.

    Read More....
  • The third Bharat Mobility Global Expo will showcase innovations in mobility and auto sector.

    Read More....
  • The report outlines India’s potential in global chemical value chains and suggests strategic reforms.

    Read More....
  • Gill scored 254+ in a Test innings, surpassing Virat Kohli’s previous high of 254*.

    Read More....
  • MobiKwik’s broking arm can now operate in trading and settlement of equity markets.

    Read More....
  • The gas giant is six times Jupiter’s mass and lies 400 light years away from Earth.

    Read More....
  • SBI flagged fund diversion in RCom’s ₹48,216 crore loan, escalating legal risk for Anil Ambani.

    Read More....
  • Sri Lanka becomes Starlink’s third South Asian market after Bhutan and Bangladesh.

    Read More....